REFERENCES
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA
Cancer J Clin 2018;68:7–30.
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M
et al. Estimating the global cancer incidence and mortality in 2018:
GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53.
doi:10.1002/ijc.31937
- Chang LC, Huang CF, Lai MS, Shen LJ, Wu FL, Cheng WF. Prognostic
factors in epithelial ovarian cancer: A population-based study.PLoS One 2018;13: e0194993.
- Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M,
et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev2019;73:1–9. doi:10.1016/j.ctrv.2018.12.002
- Jiang Y, Sun X, Kong B, Jiang J. Antiangiogenesis therapy in ovarian
cancer patients: An updated meta-analysis for 15 randomized controlled
trials. Medicine (Baltimore) 2018;97:e11920.
doi:10.1097/MD.0000000000011920
- Wu YS, Shui L, Shen D, Chen X. Bevacizumab combined with chemotherapy
for ovarian cancer: an updated systematic review and meta-analysis of
randomized controlled trials. Oncotarget 2017;8:10703–13.
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al.
Incorporation of bevacizumab in the primary treatment of ovarian
cancer. N Engl J Med 2011;365:2473–83.
doi:10.1056/NEJMoa1104390
- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E,
Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer
[published correction appears in N Engl J Med. 2012 Jan
19;366(3):284]. N Engl J Med 2011;365: 2484–96.
doi:10.1056/NEJMoa1103799
- Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF et
al. Final Overall Survival of a Randomized Trial of Bevacizumab for
Primary Treatment of Ovarian Cancer. J Clin Oncol2019;37:2317–28. doi:10.1200/JCO.19.01009
- Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA,
Pujade-Lauraine E et al. Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7):
overall survival results of a phase 3 randomised trial. Lancet
Oncol 2015;16:928–36. doi:10.1016/S1470-2045(15)00086-8
- Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final
overall survival and safety analysis of OCEANS, a phase 3 trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent ovarian cancer. Gynecol Oncol2015;139:10–6.
- Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL
et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and
secondary cytoreduction in recurrent, platinum-sensitive ovarian
cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a
multicentre, open-label, randomised, phase 3 trial. Lancet
Oncol 2017;18:779–91. doi:10.1016/S1470-2045(17)30279-6
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G
et al. Bevacizumab combined with chemotherapy for platinum-resistant
recurrent ovarian cancer: The AURELIA open-label randomized phase III
trial [published correction appears in J Clin Oncol. 2014 Dec
10;32(35):4025]. J Clin Oncol 2014;32:1302–8.
doi:10.1200/JCO.2013.51.4489
- Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C et al.
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian
cancer patients recurring after a bevacizumab containing first line
treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.J Clin Oncol 2018;36, 15 suppl:5506.
- An observational study of Avastin (bevacizumab) in combination with
carboplatin/paclitaxel in first line in patients with advanced
epithelial ovarian, fallopian tube or primary peritoneal cancer
(OTILIA) (ClinicalTrials.gov Identifier: NCT01697488)
- Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC et al. Role of
front-line bevacizumab in advanced ovarian cancer: the OSCAR study
[published online ahead of print, 27 November 2019]. Int J
Gynecol Cancer 2019, ijgc-2019-000512. doi:10.1136/ijgc-2019-000512
- Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A et al.
Bevacizumab combined with platinum-taxane chemotherapy as first-line
treatment for advanced ovarian cancer: a prospective observational
study of safety and efficacy in Japanese patients (JGOG3022
trial). Int J Clin Oncol 2019; 24:103–14. doi:
10.1007/s10147-018-1319-y.
- Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K et al.
Comparison of bevacizumab alone or with chemotherapy in recurrent
ovarian cancer patients. Gynecol Oncol 2015;139:413–8.
doi:10.1016/j.ygyno.2015.06.041
- Previs RA, Spinosa D, Fellman BM, Lorenzo A, Mulder I, Mahmound M et
al. Bevacizumab beyond progression: Impact of subsequent bevacizumab
retreatment in patients with ovarian, fallopian tube, and peritoneal
cancer after progression. J Clin Oncol 2019;37,15 suppl: 5557
- Lee JY, Park JY, Park SY, Lee JW, Kim JW, Kim YB et al. Real-world
effectiveness of bevacizumab based on AURELIA in platinum-resistant
recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group
study (KGOG 3041). Gynecol Oncol 2019;152:61–7.
doi:10.1016/j.ygyno.2018.10.031
- Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J
et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement
on clinical trials in ovarian cancer: report from the Fourth Ovarian
Cancer Consensus Conference. Int J Gynecol Cancer2011;21:750–5. doi:10.1097/IGC.0b013e31821b2568
- Huang YF, Kuo MT, Liu YS, Cheng YM, Wu PY, Chou CY. A dose escalation
study of trientine plus carboplatin and pegylated liposomal
doxorubicin in women with platinum-resistant/-refractory or partially
platinum-sensitive epithelial ovarian, tubal and peritoneal cancer.Front Oncol 2019;9:437. doi: 10.3389/fonc.2019.00437
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A et al.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian
Cancer. N Engl J Med 2016;375:2154–64.
doi:10.1056/NEJMoa1611310
- Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A et al.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after
response to platinum therapy (ARIEL3): a randomised, double-blind,
placebo-controlled, phase 3 trial [published correction appears in
Lancet. 2017 Oct 28;390(10106):1948]. Lancet2017;390:1949–61. doi:10.1016/S0140-6736(17)32440-6
- Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM
et al. Olaparib tablets as maintenance therapy in patients with
platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation
(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled,
phase 3 trial [published correction appears in Lancet Oncol. 2017
Sep;18(9):e510]. Lancet Oncol 2017;18:1274–84.
doi:10.1016/S1470-2045(17)30469-2.
- Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A,
Berger R et al. Olaparib plus Bevacizumab as First-Line Maintenance in
Ovarian Cancer. N Engl J Med 2019;381:2416–28.
doi:10.1056/NEJMoa1911361
- Wu YH, Chang TH, Huang YF, Chen CC, Chou CY. COL11A1 confers
chemoresistance on ovarian cancer cells through the activation of
Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget2015;6:23748–63. doi:10.18632/oncotarget.4250
- Wu YH, Huang YF, Chang TH, Chou CY. Activation of TWIST1 by COL11A1
promotes chemoresistance and inhibits apoptosis in ovarian cancer
cells by modulating NF-κB-mediated IKKβ expression. Int J
Cancer 2017;141:2305–17. doi:10.1002/ijc.30932
- Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH et al.
Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3)
is associated with chemoresistance and poor disease outcome in ovarian
cancer. Br J Cancer 2015;113:414–24. doi:10.1038/bjc.2015.254
- Chen WC, Qiu JT, Lai CH, Huang HJ, Lin CT, Chen MY et al. Outcomes and
prognoses of patients with ovarian cancer using bevacizumab: 6-year
experience in a tertiary care hospital of northern Taiwan. PLoS
One 2017;12:e0175703. doi:10.1371/journal.pone.0175703
- Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL et al. Trends in
incidence and survival outcome of epithelial ovarian cancer: 30-year
national population-based registry in Taiwan. J Gynecol Oncol2013;24:342–51. doi:10.3802/jgo.2013.24.4.342
- Lee SP, Hsu HC, Tai YJ, Chen YL, Chiang YC, Chen CA et al. Bevacizumab
Dose Affects the Severity of Adverse Events in Gynecologic
Malignancies. Front Pharmacol 2019;10:426.
doi:10.3389/fphar.2019.00426